{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:18:49Z","timestamp":1775513929119,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12094-021-02605-w","type":"journal-article","created":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T05:03:12Z","timestamp":1618030992000},"page":"2030-2035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-5043","authenticated-orcid":false,"given":"L.","family":"Gutierrez-Sainz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Martinez-Recio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Higuera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. I.","family":"Esteban-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Arias-Lotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. A.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"De Castro-Carpe\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,10]]},"reference":[{"issue":"4","key":"2605_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3978\/j.issn.2225-319X.2012.11.04","volume":"1","author":"BM Robinson","year":"2012","unstructured":"Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491\u20136. https:\/\/doi.org\/10.3978\/j.issn.2225-319X.2012.11.04.","journal-title":"Ann Cardiothorac Surg"},{"issue":"13","key":"2605_CR2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1186\/1471-2407-13-528","volume":"6","author":"G L\u00f3pez-Abente","year":"2013","unstructured":"L\u00f3pez-Abente G, Garc\u00eda-G\u00f3mez M, Men\u00e9ndez-Navarro A, Fern\u00e1ndez-Navarro P, et al. Pleural cancer mortality in Spain: time-trends and updating of predictions up to 2020. BMC Cancer. 2013;6(13):528. https:\/\/doi.org\/10.1186\/1471-2407-13-528.","journal-title":"BMC Cancer"},{"issue":"1","key":"2605_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cncr.21971","volume":"107","author":"JD Tward","year":"2006","unstructured":"Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107(1):108\u201315. https:\/\/doi.org\/10.1002\/cncr.21971.","journal-title":"Cancer"},{"issue":"2","key":"2605_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1700\/1088.11931","volume":"98","author":"M Comar","year":"2012","unstructured":"Comar M, Zanotta N, Pesel G, Visconti P, et al. Asbestos and SV40 in malignant pleural mesothelioma from a hyperendemic area of north-eastern Italy. Tumori. 2012;98(2):210\u20134. https:\/\/doi.org\/10.1700\/1088.11931.","journal-title":"Tumori"},{"issue":"28","key":"2605_CR5","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou V, Gadiraju M, Wolin A, Weipert CM, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018;36(28):2863\u201371. https:\/\/doi.org\/10.1200\/JCO.2018.78.5204.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2605_CR6","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, et al. WHO Panel. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243\u201360. https:\/\/doi.org\/10.1097\/JTO.0000000000000630.","journal-title":"J Thorac Oncol"},{"key":"2605_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02532-2","author":"E Nadal","year":"2021","unstructured":"Nadal E, Bosch-Barrera J, Cedr\u00e9s S, Coves J, et al. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). Clin Transl Oncol. 2021. https:\/\/doi.org\/10.1007\/s12094-020-02532-2.","journal-title":"Clin Transl Oncol"},{"issue":"14","key":"2605_CR8","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344. https:\/\/doi.org\/10.1200\/JCO.2003.11.136.","journal-title":"J Clin Oncol"},{"issue":"10026","key":"2605_CR9","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, et al. French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(15)01238-6.","journal-title":"Lancet"},{"issue":"10272","key":"2605_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8.","journal-title":"Lancet"},{"issue":"12","key":"2605_CR11","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","volume":"31","author":"S Popat","year":"2020","unstructured":"Popat S, Curioni-Fontecedro A, Dafni U, Shah R, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial. Ann Oncol. 2020;31(12):1734\u201345. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.009.","journal-title":"Ann Oncol"},{"issue":"1","key":"2605_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","volume":"19","author":"DA Fennell","year":"2018","unstructured":"Fennell DA, Kirkpatrick E, Cozens K, Nye M, et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials. 2018;19(1):233. https:\/\/doi.org\/10.1186\/s13063-018-2602-y.","journal-title":"Trials"},{"issue":"4","key":"2605_CR13","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.21037\/tlcr-19-686","volume":"9","author":"L Cantini","year":"2020","unstructured":"Cantini L, Belderbos RA, Gooijer CJ, Dumoulin DW, et al. Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program. Transl Lung Cancer Res. 2020;9(4):1169\u201379. https:\/\/doi.org\/10.21037\/tlcr-19-686.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"2605_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3978\/j.issn.2225-319X.2012.10.04","volume":"1","author":"HI Pass","year":"2012","unstructured":"Pass HI. Biomarkers and prognostic factors for mesothelioma. Ann Cardiothorac Surg. 2012;1(4):449\u201356. https:\/\/doi.org\/10.3978\/j.issn.2225-319X.2012.10.04.","journal-title":"Ann Cardiothorac Surg"},{"issue":"1","key":"2605_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","volume":"16","author":"D Curran","year":"1998","unstructured":"Curran D, Sahmoud T, Therasse P, van Meerbeeck J, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145\u201352. https:\/\/doi.org\/10.1200\/JCO.1998.16.1.145.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2605_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.113.3.723","volume":"113","author":"JE Herndon","year":"1998","unstructured":"Herndon JE, Green MR, Chahinian AP, Corson JM, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and Leukemia Group B. Chest. 1998;113(3):723\u201331. https:\/\/doi.org\/10.1378\/chest.113.3.723.","journal-title":"Chest"},{"key":"2605_CR17","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/1097-0142(19930715)72:2<410::AID-CNCR2820720216>3.0.CO;2-G","volume":"72","author":"MV De Pangher","year":"1993","unstructured":"De Pangher MV, Brollo A, et al. Prognostic factors of malignant mesothelioma of the pleura. Cancer. 1993;72:410\u20137.","journal-title":"Cancer"},{"key":"2605_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0169-5002(92)90005-5","volume":"8","author":"L Tammilehto","year":"1992","unstructured":"Tammilehto L. Malignant mesothelioma: prognostic factors in a prospective study of 98 patients. Lung Cancer. 1992;8:175\u201384.","journal-title":"Lung Cancer"},{"issue":"4","key":"2605_CR19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","volume":"135","author":"M Anraku","year":"2008","unstructured":"Anraku M, Cunningham KS, Yun Z, Tsao MS, et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2008;135(4):823\u20139. https:\/\/doi.org\/10.1016\/j.jtcvs.2007.10.026.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"11","key":"2605_CR20","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493-503. https:\/\/doi.org\/10.1016\/S1470-2045(14)70263-3.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2605_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218\u201330. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.03.010.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"2605_CR22","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/CAD.0000000000000488","volume":"28","author":"G Wood","year":"2017","unstructured":"Wood G, Grenader T, Nash S, Adams R, et al. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study. Anticancer Drugs. 2017;28(5):546\u201350. https:\/\/doi.org\/10.1097\/CAD.0000000000000488.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"2605_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.radonc.2017.08.023","volume":"125","author":"S Cox","year":"2017","unstructured":"Cox S, Hurt C, Grenader T, Mukherjee S, et al. The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017;125(1):154\u20139.","journal-title":"Radiother Oncol"},{"issue":"4","key":"2605_CR24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/annonc\/mdw016","volume":"27","author":"PF Ferrucci","year":"2016","unstructured":"Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27(4):732\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw016.","journal-title":"Ann Oncol"},{"issue":"3","key":"2605_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"Mezquita L, Auclin E, Ferrara R, Charrier M, et al. Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4771.","journal-title":"JAMA Oncol"},{"issue":"8","key":"2605_CR26","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","volume":"11","author":"Y Ohigashi","year":"2005","unstructured":"Ohigashi Y, Sho M, Yamada Y, Tsurui Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11(8):2947\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1469.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2605_CR27","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360\u20135. https:\/\/doi.org\/10.1073\/pnas.0611533104.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2605_CR28","doi-asserted-by":"publisher","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","volume":"10","author":"S Cedr\u00e9s","year":"2015","unstructured":"Cedr\u00e9s S, Ponce-Aix S, Zugazagoitia J, Sansano I, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE. 2015;10(3):e0121071. https:\/\/doi.org\/10.1371\/journal.pone.0121071.","journal-title":"PLoS ONE"},{"key":"2605_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.032","volume":"71","author":"S Inaguma","year":"2018","unstructured":"Inaguma S, Lasota J, Wang Z, Czapiewski P, et al. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma. Hum Pathol. 2018;71:1\u20137. https:\/\/doi.org\/10.1016\/j.humpath.2017.04.032.","journal-title":"Hum Pathol"},{"issue":"1","key":"2605_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/ajco.12788","volume":"14","author":"BH Nguyen","year":"2018","unstructured":"Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma. Asia Pac J Clin Oncol. 2018;14(1):69\u201373. https:\/\/doi.org\/10.1111\/ajco.12788.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"2605_CR31","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s11033-019-04715-9","volume":"46","author":"N Sobhani","year":"2019","unstructured":"Sobhani N, Roviello G, Pivetta T, Ianza A, et al. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma. Mol Biol Rep. 2019;46(3):2713\u201320. https:\/\/doi.org\/10.1007\/s11033-019-04715-9.","journal-title":"Mol Biol Rep"},{"issue":"12","key":"2605_CR32","doi-asserted-by":"publisher","first-page":"175883592096236","DOI":"10.1177\/1758835920962362","volume":"29","author":"L Jin","year":"2020","unstructured":"Jin L, Gu W, Li X, Xie L, et al. PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study. Ther Adv Med Oncol. 2020;29(12):1758835920962362. https:\/\/doi.org\/10.1177\/1758835920962362.","journal-title":"Ther Adv Med Oncol"},{"key":"2605_CR33","unstructured":"Clinicaltrials.gov. BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03762018."},{"key":"2605_CR34","unstructured":"Clinicaltrials.gov. DREAM3R: DuRvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04334759."},{"key":"2605_CR35","unstructured":"Clinicaltrials.gov. IND.227: Pembrolizumab in patients with advanced malignant pleural mesothelioma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02784171."},{"issue":"23","key":"2605_CR36","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","volume":"16","author":"SC Kao","year":"2010","unstructured":"Kao SC, Pavlakis N, Harvie R, Vardy JL, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010;16(23):5805\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2245.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2605_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cllc.2012.03.011","volume":"14","author":"SC Kao","year":"2013","unstructured":"Kao SC, Vardy J, Chatfield M, Corte P, et al. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer. 2013;14(1):70\u20137. https:\/\/doi.org\/10.1016\/j.cllc.2012.03.011.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"2605_CR38","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","volume":"77","author":"S Cedr\u00e9s","year":"2012","unstructured":"Cedr\u00e9s S, Montero MA, Martinez P, Martinez A, et al. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer. 2012;77(1):192\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2012.02.022.","journal-title":"Lung Cancer"},{"issue":"11","key":"2605_CR39","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","volume":"6","author":"SC Kao","year":"2011","unstructured":"Kao SC, Klebe S, Henderson DW, Reid G, et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol. 2011;6(11):1923\u20139. https:\/\/doi.org\/10.1097\/JTO.0b013e31822a3740.","journal-title":"J Thorac Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02605-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02605-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02605-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T21:24:22Z","timestamp":1630013062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02605-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2605"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02605-w","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,10]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the La Paz University Hospital, and was conducted in accordance with ethical standards of the Helsinki Declaration of the World Medical Association.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and compliance with ethical standards"}},{"value":"Local ethical committee approved the use of anonymized historic data for the study and waived informed consent from patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}